Akebia Therapeutics, a biotech developing treatments for anemia, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The Cambridge, MA-based company, which was founded in 2007, plans to list on the NASDAQ under the symbol AKBA. Akebia Therapeutics initially filed confidentially on December 20, 2013. Morgan Stanley, Credit Suisse and UBS are the joint bookrunners on the deal. No pricing terms were disclosed.
